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http://dx.doi.org/1diuretics. The clinical proﬁle and prognostic signiﬁcance of serum magnesium level
concentration in patients hospitalized for heart failure (HF) with reduced ejection fraction is
unclear. In this retrospective analysis of the placebo group of the Efﬁcacy of Vasopressin
Antagonism in Heart Failure Outcome Study with Tolvaptan trial, we evaluated 1,982
patients hospitalized for worsening HF with ejection fractions £40%. Baseline magnesium
levels were measured within 48 hours of admission and analyzed as a continuous variable
and in quartiles. The primary end points of all-cause mortality (ACM) and cardiovascular
mortality or HF rehospitalization were analyzed using Cox regression models. Mean baseline
magnesium level was 2.1 – 0.3 mg/dl. Compared with the lowest quartile, patients in the
highest magnesium level quartile were more likely to be older, men, have lower heart rates
and blood pressures, have ischemic HF origin, and have higher creatinine and natriuretic
peptide levels (all p <0.003). During a median follow-up of 9.9 months, every 1-mg/dl
increase in magnesium level was associated with higher ACM (hazard ratio [HR] 1.77; 95%
conﬁdence interval [CI] 1.35 to 2.32; p <0.001) and the composite end point (HR 1.44; 95%CI
1.15 to 1.81; p [ 0.002). However, after adjustment for known baseline covariates, serum
magnesium level was no longer an independent predictor of either ACM (HR 0.94, 95% CI
0.69 to 1.28; p[ 0.7) or the composite end point (HR 1.01, 95% CI 0.79 to 1.30; p[ 0.9). In
conclusion, despite theoretical concerns, baseline magnesium level was not independently
associated with worse outcomes in this cohort. Further research is needed to understand the
importance of serum magnesium levels in speciﬁc HF patient populations.  2013 Elsevier
Inc. All rights reserved. (Am J Cardiol 2013;112:1763e1769)Magnesium, the second most common intracellular
cation, plays an integral role in myocardial membrane
function, enzymatic reactions, and intracellular transport.1
Investigations in chronic heart failure (HF) are conﬂicting
regarding the prognostic role of varying magnesium
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0.1016/j.amjcard.2013.07.020consistently linked to increased premature ventricular
contractions3 and potentially increased arrhythmogenesis.4
The inpatient setting is marked by disturbances to magne-
sium homeostasis including diuretic therapy, heightened
neurohormonal activation, impaired gastrointestinal absorp-
tion (secondary to gut edema), renal insufﬁciency, and poor
nutritional intake. Data regarding the association between
serum magnesium levels during hospitalization for HF and
clinical outcomes are limited and generally inconsistent. In
a small single-center study (n¼ 404), Cohen et al5 found that
aberrations in serum magnesium levels (both hyper- and
hypomagnesemia) at the time of hospitalization were asso-
ciated with an increased postdischarge mortality. However,
after adjustment for clinical variables, only low serum
magnesium level retained prognostic utility.5 An Italian
study with follow-up up to 3 years showed that hyper-
magnesemia was associated with increased mortality in
elderly patients with HF.6 These incongruent data highlight
the need for more robust and complete characterization of the
clinical proﬁles and prognostic impact of serum magnesium
levels during hospitalization for HF. The Efﬁcacy of Vaso-
pressin Antagonism in Heart Failure Outcome Study with
Tolvaptan (EVEREST)7,8,9 dataset provides insight into
the longitudinal electrolyte proﬁles in a large cohort of
hospitalized patients with HF. Thus, we investigated thewww.ajconline.org
Figure 1. Overall study design and analytical cohort selection. LVEF ¼ left ventricular ejection fraction; Q ¼ quartile.
Figure 2. Distribution and descriptive statistics of serum magnesium levels.
The primary predictor variable of baseline serum magnesium level was
normally distributed with a mean and median of approximately 2.1 mg/dl.
The black curve represents the normal density distribution and the gray
curve represents the kernel density distribution for this sample. The gray
box represents the interquartile range (25th to 75th percentile).
1764 The American Journal of Cardiology (www.ajconline.org)association between baseline serum magnesium levels and
postdischarge outcomes in patients hospitalized for HF with
reduced ejection fraction (EF).
Methods
The study design8 and primary results7,9 of the EVEREST
trial have been previously published. In brief, EVEREST
was a multicenter, international, double-blinded, placebo-
controlled, randomized trial evaluating tolvaptan, an oral
vasopressin-2 receptor antagonist. The trial included patients
hospitalized for HF with New York Heart Association
(NYHA) functional class III or IV symptoms, EF of 40%,
and signs and symptoms of ﬂuid overload. Relevant exclu-
sion criteria include a serum creatinine level of >3.5 mg/dl,
serum potassium level of >5.5 mEq/L, and co-morbid
conditions with life expectancy <6 months.
The ethics committee and institutional review board of
each participating site approved the study protocol. After
providing informed consent, the study participants were
randomized to receive oral tolvaptan at a 30-mg ﬁxed dose
or matching placebo within 48 hours of hospital admission
and was continued for at least 60 days. Concomitant medical
therapies were left to the discretion of the treating physician.
Because tolvaptan modestly increased serum magnesium
levels as early as day 1 after randomization,7,9 this analysis
was restricted to the placebo cohort. Laboratory samples
were collected, processed, and cross-validated across 5
central facilities. Serum magnesium level (mg/dl) was
measured at the time of study enrollment (baseline, up to
48 hours after admission) and every 4 to 8 weeks up to112 weeks after discharge. Baseline magnesium level,
expressed as a continuous function (per 1-mg/dl increase),
was the primary predictor in this post hoc analysis. No
nonlinear effects were detected; thus, no transformation of
data was undertaken. However, for descriptive purposes,
subjects were divided by magnesium level quartiles. The
overall study design and ﬁnal analytical cohort selection are
displayed in Figure 1.
Table 1
Baseline characteristics by baseline serum magnesium level quartile
Characteristics Magnesium Level Quartiles (mg/dl) p
Q1 (0.8e1.8),
n ¼ 411
Q2 (1.9e2.0),
n ¼ 595
Q3 (2.1e2.2),
n ¼ 556
Q4 (2.3e4.1),
n ¼ 420
Magnesium level (mean  SD) 1.7  0.2 2  0 2.1  0 2.5  0.2 <0.001
Age (mean  SD; yrs) 63.4  11.7 64.6  11.9 66.6  11.9 67.7  12.5 <0.001
Men 284 (69.1) 449 (75.5) 424 (76.3) 336 (80) 0.003
Body mass index (median [IQR]; kg/m2) 28.6 (24.7e32.5) 27.4 (24.3e31.9) 27.8 (24.7e32.3) 28.0 (24.6e31.2) 0.336
Ejection fraction (mean  SD; %) 27.3  8.3 28  8 27.9  8.3 26.9  8.2 0.118
QRS duration (mean  SD; ms) 120.6  31.9 122.6  32.4 127.4  35.3 137.3  38.2 <0.001
Atrial ﬁbrillation or ﬂutter 133 (32.4) 172 (29) 160 (28.8) 107 (25.5) 0.188
Ischemic origin of HF 252 (62.5) 368 (62.4) 370 (67.5) 301 (72.5) 0.003
NYHA class IV 185 (45) 234 (39.3) 184 (33.2) 189 (45.1) <0.001
Coronary artery disease 278 (68) 406 (68.4) 397 (71.4) 315 (75) 0.076
Hypertension 296 (72) 432 (72.6) 389 (70) 298 (71) 0.776
Hyperlipidemia 179 (43.8) 267 (45.1) 266 (48) 225 (53.7) 0.017
Diabetes mellitus 185 (45) 210 (35.3) 196 (35.3) 153 (36.4) 0.006
Chronic kidney disease 76 (18.5) 123 (20.7) 156 (28.1) 183 (43.6) <0.001
Dyspnea 360 (88.7) 536 (91.5) 506 (92.3) 376 (91.5) 0.243
Jugular venous distension 118 (29.4) 138 (23.8) 142 (26.2) 122 (29.8) 0.108
Rales 329 (81) 476 (81.2) 449 (81.8) 343 (83.3) 0.833
Pedal edema* 325 (79.9) 459 (78.3) 442 (80.5) 333 (80.8) 0.746
Systolic blood pressure (mean  SD; mm Hg) 121.5  19.3 122.7  19.6 120.3  19.5 115.6  18.4 <0.001
Heart rate (mean  SD; beats/min) 82.5  16.3 80.3  15.8 78  14.6 78.2  15.5 <0.001
Albumin (mean  SD; g/dl) 3.6  0.5 3.7  0.5 3.8  0.5 3.8  0.5 <0.001
B-type natriuretic peptide (median [IQR]; pg/ml)† 789 (392e1,594) 675 (301e1,417) 631 (272e1,417) 890 (372e1,860) 0.008
Blood urea nitrogen (mean  SD; g/dl) 25.1  11.8 26  11.5 30.7  15.3 41.5  23.1 <0.001
Creatinine (mean  SD; mg/dl) 1.2  0.4 1.3  0.4 1.4  0.7 1.7  0.6 <0.001
Serum sodium (mean  SD; mEq/L) 138.9  4.5 139.8  4.3 140  4.8 139.7  5.4 0.006
Baseline medications
ACE inhibitor or ARB 355 (86.6) 505 (85.3) 470 (84.8) 337 (80.2) 0.059
Mineralocorticoid receptor antagonist 234 (57.1) 337 (56.9) 292 (52.7) 228 (54.3) 0.419
b blocker 288 (70.2) 406 (68.6) 398 (71.8) 294 (70) 0.692
Digoxin 227 (55.4) 294 (49.7) 268 (48.4) 179 (42.6) 0.003
Diuretics 401 (97.8) 573 (96.8) 537 (96.9) 410 (97.6) 0.720
Statins 127 (31) 182 (30.7) 196 (35.4) 155 (36.9) 0.100
Categorical variables are reported as number of patients (percentage). Continuous variables are presented as mean  SD (if normally distributed) or median
(IQR; if nonenormally distributed).
ACE ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; IQR ¼ interquartile range.
* Peripheral edema was deﬁned as slight, moderate, or marked pedal or sacral edema.
† B-type natriuretic peptide data are available for 270, 436, 418, and 313 patients for Q1 to 4, respectively.
Heart Failure/Magnesium in Heart Failure 1765Demographic characteristics, clinical history, signs and
symptoms of HF, vital signs, laboratory parameters, and
admission medications were compared across quartiles of
baseline magnesium levels. An independent blinded adjudi-
cation committee determined the speciﬁc causes of death and
reasons for rehospitalization. The present post hoc analysis
used the same 2 coprimary end points as the overall EVER-
EST trial: all-cause mortality (ACM) and a composite end
point of cardiovascular (CV) mortality or HF hospitalization.
Secondary end points included other causes of death and
rehospitalization, worsening HF (deﬁned as death, hospitali-
zation, or unplanned ofﬁce visit for HF), and combined CV
mortality and rehospitalization. Median follow-up was
9.9 months (interquartile range, 5.3 to 16.1 months).
Continuous variables are expressed as mean  SD if
normally distributed and median (interquartile range) if
nonenormally distributed. Categorical variables are expressed
as number (percentage). Outcomes were assessed as time toﬁrst event using Cox proportional hazard models. Kaplan-
Meier curves by serum magnesium level quartile were con-
structed for both primary end points and compared using
log-rank tests. The proportional hazards assumption (by Kol-
mogorov-type supremum tests for nonproportionality) was
upheld for both primary end points. Effect sizes were reported
as hazard ratios (HRs) with 95% conﬁdence intervals (CIs).
Multivariate models included 23 prespeciﬁed covariates
including demographic characteristics (age, gender, and region
of origin), clinical characteristics (ischemic HF origin, atrial
ﬁbrillation on admission electrocardiogram, coronary artery
disease, diabetes, hypertension, chronic obstructive pulmo-
nary disease, chronic kidney disease [CKD, deﬁned as an
estimated glomerular ﬁltration rate <60 ml/min/1.73 m2],
NYHA class IV, vital signs [supine systolic blood pressure],
and laboratory and diagnostic testing [QRS duration on
admission electrocardiogram, EF, serum sodium, serum
potassium, blood urea nitrogen, B-type natriuretic peptide]),
Table 2
Causes of death and reasons for rehospitalization by baseline serum magnesium level quartile
Characteristics Magnesium Level Quartiles (mg/dl) p
Q1 (0.8e1.8), n ¼ 411 Q2 (1.9e2.0), n ¼ 595 Q3 (2.1e2.2), n ¼ 556 Q4 (2.3e4.1), n ¼ 420
Primary end points
ACM 94 (22.9) 146 (24.5) 144 (25.9) 140 (33.3) 0.003
CV mortality and HF hospitalization 149 (36.3) 230 (38.7) 231 (41.5) 187 (44.5) 0.074
Causes of death
CV 69 (16.8) 113 (19) 105 (18.9) 109 (26) 0.005
Sudden cardiac death 26 (6.3) 43 (7.2) 37 (6.7) 23 (5.5) 0.733
HF 28 (6.8) 55 (9.2) 55 (9.9) 77 (18.3) <0.001
Myocardial infarction 5 (1.2) 3 (0.5) 3 (0.5) 4 (1) 0.527
Stroke 3 (0.7) 3 (0.5) 1 (0.2) 1 (0.2) 0.529
Other CV 7 (1.7) 9 (1.5) 9 (1.6) 4 (1) 0.795
Non-CV 17 (4.1) 20 (3.4) 21 (3.8) 19 (4.5) 0.805
Reasons for rehospitalization
CV 140 (34.1) 213 (35.8) 228 (41) 168 (40) 0.080
HF 100 (24.3) 157 (26.4) 162 (29.1) 121 (28.8) 0.320
Myocardial infarction 8 (1.9) 7 (1.2) 8 (1.4) 6 (1.4) 0.799
Stroke 4 (1) 5 (0.8) 6 (1.1) 3 (0.7) 0.939
Arrhythmia 11 (2.7) 17 (2.9) 13 (2.3) 15 (3.6) 0.713
Other CV 17 (4.1) 27 (4.5) 39 (7) 23 (5.5) 0.170
Worsening HF* 127 (30.9) 198 (33.3) 214 (38.5) 172 (41) 0.006
CV mortality and rehospitalization 178 (43.3) 257 (43.2) 273 (49.1) 213 (50.7) 0.032
Outcomes are resulted as number of events (percentage) by quartile of baseline serum magnesium levels.
* Worsening HF was deﬁned as death from HF, hospitalization for HF, or unscheduled medical ofﬁce visit for HF.
1766 The American Journal of Cardiology (www.ajconline.org)and baseline medication use (angiotensin-converting enzyme
inhibitors or angiotensin II receptor blockers, b blockers,
mineralocorticoid receptor antagonists, digoxin, and intrave-
nous inotropes). Multiple imputation procedures (fully
conditional speciﬁcation method) were used to impute any
missing covariate data (w27% for natriuretic peptides, 4% for
QRS duration, 2% for ischemic HF origin, and 1% for all
other variables). No evidence of signiﬁcant collinearity
between baseline magnesium levels and the covariate set was
detected (tolerance, 0.81). Separate interaction analyses were
performed for CKD, diabetes, and ischemic HF origin. All
statistical analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, North Carolina).
Results
Of the 2,061 patients in the EVEREST placebo arm, 79
patients had missing serum magnesium levels at the time of
enrollment. Serum magnesium level was normally distrib-
uted (Figure 2) in the remaining analytical cohort (n ¼
1,982) with a mean of 2.1  0.3 mg/dl, ranging from 0.8 to
4.1 mg/dl. Table 1 lists the baseline characteristics across
magnesium level quartiles. Patients in the higher magnesium
level quartiles tended to be older, men, and had lower pre-
senting heart rates and systolic blood pressures (all p
<0.003). Patients with higher magnesium levels also tended
to have wider QRS durations on admission electrocardio-
gram and were more likely to have ischemic origin of HF
and NYHA class IV symptoms (all p <0.003). Higher
baseline magnesium level was associated with higher rates
of CKD and higher initial serum creatinine and blood urea
nitrogen levels (all p <0.001). The only between-group
medication difference was for digoxin, which was lesscommonly prescribed in the higher magnesium level quar-
tiles (p ¼ 0.003). Signiﬁcant differences across quartiles
were noted for diabetes, B-type natriuretic peptide levels,
and serum sodium, but no clear trend was identiﬁed. Of
note, no differences were observed in mean EF and signs
and symptoms of HF across magnesium level quartiles.
During a median follow-up of 9.9 months, 524 placebo
patients experienced ACM, whereas 797 experienced the
composite end point of CV mortality or HF hospitalization
(Table 2). Rates of ACM increased from 22.9% in quartile 1
to 33.3% in quartile 4 of baseline magnesium levels (p ¼
0.003). Similarly, rates of the composite outcome increased
from 36.3% to 44.5% across the 4 quartiles (p ¼ 0.074).
Analysis of secondary outcomes revealed signiﬁcant
increases in rates of CV mortality (p ¼ 0.005), HF mortality
(p <0.001), worsening HF (p ¼ 0.006), and combined CV
mortality and rehospitalization (p ¼ 0.032), with increased
serum magnesium level quartiles. Other secondary outcomes
did not signiﬁcantly differ by magnesium level quartile.
Times to ﬁrst event were also signiﬁcantly different by the
Kaplan-Meier method across magnesium level quartiles for
ACM (Figure 3; log-rank p <0.001) and CV mortality or HF
hospitalization (Figure 3; log-rank p ¼ 0.004).
In univariate analysis, every 1-mg/dl increase in
magnesium was associated with higher rates of ACM (HR
1.77; 95% CI 1.35 to 2.32; p <0.001) and the composite end
point (HR 1.44; 95% CI 1.15 to 1.81; p ¼ 0.002). However,
after adjustment for known baseline covariates, serum
magnesium level was no longer an independent predictor of
either ACM (HR 0.94, 95% CI 0.69 to 1.28; p ¼ 0.7) or the
composite end point (HR 1.01, 95% CI 0.79 to 1.30; p ¼
0.9). The association between magnesium level and ACM
differed signiﬁcantly in patients with CKD (HR 2.01, 95%
Figure 3. Kaplan-Meier curves for ACM (A) and composite CVmortality and
HF hospitalizations (B). Times to events were compared using log-rank tests.
Figure 4. Changes in serum magnesium levels over time. “Baseline”
measurement of magnesium level, which has been used for all analyses in
this study, was performed within 48 hours of hospital admission. The
overall time course of mean magnesium levels during the 112-week follow-
up has been stratiﬁed by baseline magnesium quartiles.
Heart Failure/Magnesium in Heart Failure 1767CI 1.39 to 2.90; p <0.001) versus those without CKD (HR
1.03, 95% CI 0.69 to 1.55; p ¼ 0.9). Other interaction
analyses for ischemic HF origin and diabetes were not
signiﬁcant.Although the variation across baseline quartiles of
magnesium levels was larger in magnitude during hospi-
talization, differences in serum magnesium levels persisted
up to 112 weeks after discharge (Figure 4). In the lowest
quartile of baseline magnesium levels, the levels increased
minimally from 1.7 mg/dl at baseline to approximately
1.9 mg/dl at 112 weeks.
Discussion
HF represents the most common reason for admissions
and readmissions in older adults in the United States,
accounting for roughly 4 million total hospitalizations
annually.10 Despite adherence to national performance
measures and widespread use of some evidence-based
therapies, mortality and rehospitalization approach 15% and
30%, respectively, within 60 to 90 days after discharge.11
Electrolyte proﬁles widely ﬂuctuate during and shortly after
hospitalization because of the severity of underlying disease
and therapies targeting congestion.12 Indeed, hospitalization
for HF may serve as the “perfect storm” for electrolyte
disturbances given the severe hemodynamic and neurohor-
monal perturbations12 and the widespread use of diuretics.
Magnesium is a critical cation necessary for myocardial
functioning13; thus, its levels are often closely monitored
during hospitalization and in the postdischarge timeframe.
However, the relation among serum magnesium levels, the
pathophysiology, and progression of HF and clinical
outcomes is poorly deﬁned.
This is, to the best of our knowledge, the largest study of
the prognostic value of serum magnesium levels in patients
hospitalized for HF. The distribution of serum magnesium
levels at enrollment was normally distributed around a mean
of 2.1 mg/dl. Higher presenting magnesium levels were
strongly associated with age, worse baseline renal function,
and advanced NYHA functional class. In unadjusted anal-
yses, baseline serum magnesium levels were predictive of
the coprimary end points, ACM and composite CV
mortality or HF hospitalization. The association was most
pronounced in patients with a history of CKD. However,
after accounting for the baseline differences in risk proﬁles,
baseline serum magnesium levels were not independently
associated with ACM and the composite of CV mortality or
HF hospitalization.
A study by Gottlieb et al4 demonstrated worse 1-year
survival in patients with chronic HF with serum magnesium
levels <1.6 or >2.1 mg/dl. In contrast, a study by Eichhorn
et al3 showed that serum magnesium level was not an
independent risk factor of ACM or sudden cardiac death in
1,068 patients with NYHA classes III and IV chronic HF. In
this study, although low magnesium levels were associated
with increased frequency of premature ventricular contrac-
tions, no signiﬁcant differences in clinical events were
observed.3 Consistent with our data, mortality risk associ-
ated with elevated magnesium levels was accounted for by
age, advanced HF, and renal dysfunction.3 More recently,
a robust propensity-matched post hoc analysis of the Digi-
talis Investigation Group trial revealed that ambulatory
patients with HF with serum magnesium levels <2 mEq/L
were at increased risk for CV mortality, but not hospitali-
zation during a mean follow-up of 36 months.2
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latory patients with chronic HF, and assessment of the
prognostic signiﬁcance of in-hospital magnesium levels has
not been well studied. In a small study of 404 patients
hospitalized for HF, high magnesium levels were associated
with increased age, renal failure, advanced NYHA func-
tional class, and higher-dose diuretic therapy.5 After
adjustment for these high-risk features, low but not high
magnesium level was associated with reduced survival at
43 months.5 In another study of patients admitted to an
Italian rehabilitation unit, hypermagnesemia was associated
with increased risk of mortality at 3-year follow-up.6 These
studies have been small single-center experiences with
limited covariate adjustment, likely explaining the observed
discrepancies in ﬁndings from the present investigation.
Mechanistically, deﬁciency in magnesium levels may
contribute to enhancement of calcium-mediated vasocon-
striction, disruption of myocardial membrane integrity, and
dysregulation of essential transport processes.13 Based on
theoretical risks of magnesium deﬁciency on clinical status
in HF, magnesium nutrient supplementation has been
postulated as potentially viable therapy in HF.14 The
Magnesium Orotate in Severe Congestive Heart Failure trial
demonstrated that 1-year therapy with magnesium orotate
improved survival in 79 patients with NYHA class IV HF.15
Several other small studies have shown that short-term
infusion of intravenous magnesium sulfate16 or magnesium
chloride17 reduced the frequency of ventricular ectopy.
However, in a recent large retrospective analysis of the
Women’s Health Initiative including 3,350 patients hospi-
talized for incident HF, magnesium supplementation was
not associated with postdischarge mortality during a median
follow-up of 4.6 years.18
In our study, QRS duration was found to be more pro-
longed in higher quartiles of baseline serum magnesium
levels. Consistently, short-term infusion of magnesium
sulfate prolongs QRS durations in rat models, but leads to
suppression of ventricular arrhythmias.19 Varying electro-
lyte proﬁles and their interaction with QRS duration may
have important implications for the placement of cardiac
resynchronization therapy devices in patients with HF.
Furthermore, patients with higher baseline serum magne-
sium levels were found to have lower mean heart rates and
systolic blood pressures. Extrapolation of data from ambu-
latory patients and animal models20,21 suggest that magne-
sium may inhibit calcium inﬂux and intracellular calcium
content, thus attenuating the overall sympathetic response,
perhaps explaining these hemodynamic trends.
The primary limitations of this analysis are related to the
post hoc nature of the study design. Despite robust multi-
variate modeling, residual confounding by unmeasured
parameters may remain. The EVEREST trial included
a highly selected cohort of hospitalized patients with HF and
excluded patients with severe CKD and elevated potassium
at the time of enrollment. Given the co-regulation of these
cations in humans, these enrollment criteria may affect the
study population and distribution of magnesium levels.
Similar to potassium, serum magnesium levels represent
<1% of total body stores; thus, measured levels may not
truly affect biologically active stores. The study did adjust
for potassium levels at baseline in our multivariate models.Our study did not account for diuretic dosing and adequacy
of electrolyte repletion during hospitalization. Although the
analysis was based on the baseline serum magnesium level,
which may be subject to a certain degree of error, quartiles
of magnesium levels remained relatively stable and sepa-
rated on serial measurements. No data were available on the
use of magnesium supplements at the time of admission or
discharge. The range of magnesium levels is fairly
restricted, and thus, patients at the extremes of the magne-
sium spectrum may not be well represented. Future studies
are warranted to evaluate HF subgroups, speciﬁcally those
with especially low magnesium levels, those with concom-
itant electrolyte disturbances, and those who are not actively
repleted.
Demographic and clinical characteristics in patients
hospitalized for HF varied signiﬁcantly by baseline serum
magnesium levels. Differences in magnesium levels on
presentation to the hospital persist into the late post-
discharge period. Higher levels of magnesium are associated
with increased risk of postdischarge outcomes in patients
hospitalized for HF in unadjusted analyses. On multivariate
analyses, baseline serum magnesium level was not inde-
pendently associated with ACM or the composite of CV
death or HF hospitalization. The excess risk associated with
higher magnesium levels is likely attributable to older age,
renal dysfunction, and worse baseline NYHA class rather
than magnesium levels per se. Future prospective investi-
gations are required to determine the optimal degree and
method of magnesium repletion in patients hospitalized for
HF, especially in high-risk subgroups such as those with
baseline CKD.Disclosures
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